Bradley Torphy, MD
Family Medicine · Chicago, ILNPI 1104052372
Payments from drug & device makers
Across 2,408 payments — averaging $1233.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1.6M
- Amgen$350K
- Teva Pharmaceuticals USA, Inc.$209K
- Eli Lilly$188K
- Lilly USA, LLC$150K
- Pfizer$107K
- plus $328K from 25 others
Across 7 payments — averaging $3475.46 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$13K
- Pfizer$10K
- Eli Lilly$1K
What the payments were for
- Consulting fees$134,78410%
- Speaking & faculty fees$1,098,82082%
- Grants$420%
- Travel & lodging$75,2976%
- Food & beverage$38,2593%
- Education$4450%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 955 | $1,637,925 |
| Amgen | 262 | $350,202 |
| Teva Pharmaceuticals USA, Inc. | 226 | $209,369 |
| Eli Lilly | 19 | $188,233 |
| Lilly USA, LLC | 337 | $150,484 |
| Pfizer | 83 | $106,528 |
| Ipsen Innovation | 86 | $86,781 |
| Biohaven Pharmaceutical Holding Company Ltd. | 63 | $60,674 |
| Axsome Therapeutics, Inc. | 34 | $46,769 |
| Lundbeck LLC | 76 | $44,911 |
| H. Lundbeck A S | 18 | $32,579 |
| Impel Pharmaceuticals Inc. | 47 | $24,573 |
| Biohaven Pharmaceuticals, Inc. | 52 | $18,855 |
| Novartis | 21 | $5,676 |
| Promius Pharma LLC | 9 | $4,191 |
| Upsher-smith Laboratories LLC | 31 | $638 |
| Tonix Medicines, Inc. | 5 | $601 |
| Supernus Pharmaceuticals, Inc. | 24 | $414 |
| Zyla Life Sciences, Inc. | 11 | $189 |
| Amneal Pharmaceuticals LLC | 8 | $149 |
| Merck | 5 | $105 |
| Tersera Therapeutics LLC | 6 | $103 |
| Bausch Health US, LLC | 5 | $87 |
| Novo Nordisk | 1 | $87 |
| Assertio Therapeutics, Inc. | 6 | $84 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $82 |
| Impel Pharmaceuticals LLC | 3 | $74 |
| Collegium Pharmaceutical, Inc. | 3 | $64 |
| Currax Pharmaceuticals LLC | 3 | $51 |
| Vertical Pharmaceuticals, LLC | 3 | $48 |
| Otsuka America Pharmaceutical, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,970,541 in reported general payments places this provider in the 95th percentile of 4,116 family medicine providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| UbrelvyUbrogepant | 19 | $28,641 |
| Emgality PenGalcanezumab-Gnlm | 27 | $18,823 |
| QuliptaAtogepant | 11 | $18,128 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 21 | $16,644 |
| Aimovig AutoinjectorErenumab-Aooe | 11 | $15,307 |
| Sumatriptan Succinate | 34 | $9,474 |
| Gabapentin | 31 | $416 |
| Acetazolamide | 19 | $407 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 17 | $316 |
| Divalproex Sodium | 13 | $251 |
| Topiramate | 28 | $179 |
| Memantine Hcl | 11 | $166 |
| Baclofen | 28 | $101 |
| Diphenhydramine Hcl | 11 | $86 |
| Hydroxyzine Hcl | 13 | $83 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieUbrelvy, Qulipta | $1,637,925 | $46,76930 claims |
| Upsher-smith Laboratories LLCTopiramate | $638 | $17928 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,116 family medicine providers in Illinois.
Other family medicine in Chicago
- Frank PhillipsChicago$1.6M
- Ayoade AkereChicago$484K
- Sandy GibsonChicago$309K
- Mandy GittlerChicago$204K
- Jacqueline OlivoChicago$165K
- Sameer PanjwaniChicago$136K
- Igor AltmanChicago$64K
- Juan RojasChicago$40K
- Mark SimonChicago$39K
- James DelisChicago$31K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.